A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection.
Publication
, Journal Article
Knox, J; Cheng, A; Cleary, S; Galle, P; Kokudo, N; Lencioni, R; Park, J; Zhou, J; Mann, H; Morgan, S; Liu, X; Chin, S; Vlahovic, G; Fan, J
Published in: Ann Oncol
July 2019
Duke Scholars
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
July 2019
Volume
30 Suppl 4
Start / End Page
iv51
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Knox, J., Cheng, A., Cleary, S., Galle, P., Kokudo, N., Lencioni, R., … Fan, J. (2019). A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection. Ann Oncol, 30 Suppl 4, iv51. https://doi.org/10.1093/annonc/mdz155.186
Knox, J., A. Cheng, S. Cleary, P. Galle, N. Kokudo, R. Lencioni, J. Park, et al. “A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection.” Ann Oncol 30 Suppl 4 (July 2019): iv51. https://doi.org/10.1093/annonc/mdz155.186.
Knox J, Cheng A, Cleary S, Galle P, Kokudo N, Lencioni R, et al. A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection. Ann Oncol. 2019 Jul;30 Suppl 4:iv51.
Knox, J., et al. “A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection.” Ann Oncol, vol. 30 Suppl 4, July 2019, p. iv51. Pubmed, doi:10.1093/annonc/mdz155.186.
Knox J, Cheng A, Cleary S, Galle P, Kokudo N, Lencioni R, Park J, Zhou J, Mann H, Morgan S, Liu X, Chin S, Vlahovic G, Fan J. A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection. Ann Oncol. 2019 Jul;30 Suppl 4:iv51.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
July 2019
Volume
30 Suppl 4
Start / End Page
iv51
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis